{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Symptom+Clusters&page=18",
    "query": {
      "condition": "Symptom Clusters",
      "page": 18
    },
    "page_size": 10
  },
  "pagination": {
    "page": 18,
    "page_size": 10,
    "total_count": 16806,
    "total_pages": 1681,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Symptom+Clusters&page=19&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Symptom+Clusters&page=17&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-21T12:13:07.503Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00084253",
      "title": "Study of Boosted Atazanavir (ATV) Versus Non-boosted ATV in Naive Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "Atazanavir/ Stavidine / Lamivudine",
          "type": "DRUG"
        },
        {
          "name": "Atazanavir-Ritonavir/ Stavidine / Lamivudine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bristol-Myers Squibb",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 200,
      "start_date": "2004-06",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2010-03-05",
      "last_synced_at": "2026-10-21T12:13:07.503Z",
      "location_count": 1,
      "location_summary": "Call For Information, New Jersey",
      "locations": [
        {
          "city": "Call For Information",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00084253"
    },
    {
      "nct_id": "NCT01967537",
      "title": "Evaluation of 68Gallium-DOTATATE PET/CT for Detecting Neuroendocrine Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Neuroendocrine Tumors",
        "Von Hippel-Lindau Syndrome",
        "Hippel-Lindau Disease"
      ],
      "interventions": [
        {
          "name": "68Gallium DOTATATE",
          "type": "DRUG"
        },
        {
          "name": "Radio-guided surgery",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "10 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "10 Years to 99 Years"
      },
      "enrollment_count": 341,
      "start_date": "2013-10-18",
      "completion_date": "2018-03-12",
      "has_results": true,
      "last_update_posted_date": "2019-11-19",
      "last_synced_at": "2026-10-21T12:13:07.503Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01967537"
    },
    {
      "nct_id": "NCT00044837",
      "title": "Hormone Replacement Therapy and Anti-HIV Drugs in HIV-Infected, Postmenopausal Women",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "Medroxyprogesterone acetate",
          "type": "DRUG"
        },
        {
          "name": "Estradiol",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 120,
      "start_date": null,
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2015-06-04",
      "last_synced_at": "2026-10-21T12:13:07.503Z",
      "location_count": 1,
      "location_summary": "Rockville, Maryland",
      "locations": [
        {
          "city": "Rockville",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00044837"
    },
    {
      "nct_id": "NCT03414645",
      "title": "Topical Fibrinogen-Depleted Human Platelet Lysate in Patients With Dry Eye Secondary to Graft vs. Host Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Dry Eye",
        "Graft-versus-host-disease",
        "Ocular Discomfort"
      ],
      "interventions": [
        {
          "name": "CAM-101 10%",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Vehicle Control",
          "type": "BIOLOGICAL"
        },
        {
          "name": "CAM-101 30%",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Cambium Bio Limited",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 64,
      "start_date": "2018-05-01",
      "completion_date": "2020-02-20",
      "has_results": true,
      "last_update_posted_date": "2026-06-12",
      "last_synced_at": "2026-10-21T12:13:07.503Z",
      "location_count": 6,
      "location_summary": "Palo Alto, California • Boston, Massachusetts • Ann Arbor, Michigan + 3 more",
      "locations": [
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        },
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03414645"
    },
    {
      "nct_id": "NCT00828802",
      "title": "Lenalidomide and Decitabine in High Grade Myelodysplastic Syndromes",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Myelodysplastic Syndromes"
      ],
      "interventions": [
        {
          "name": "Lenalidomide, Decitabine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Duke University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 15,
      "start_date": "2009-03",
      "completion_date": "2012-11",
      "has_results": false,
      "last_update_posted_date": "2013-09-09",
      "last_synced_at": "2026-10-21T12:13:07.503Z",
      "location_count": 1,
      "location_summary": "Durham, North Carolina",
      "locations": [
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00828802"
    },
    {
      "nct_id": "NCT04798339",
      "title": "Canakinumab With Darbepoetin Alfa in PTs With Lower-Risk MDS Who Have Failed ESA",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Myelodysplastic Syndromes"
      ],
      "interventions": [
        {
          "name": "Canakinumab Injection",
          "type": "DRUG"
        },
        {
          "name": "Darbepoetin Alfa",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "H. Lee Moffitt Cancer Center and Research Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 13,
      "start_date": "2021-03-30",
      "completion_date": "2026-07",
      "has_results": false,
      "last_update_posted_date": "2025-10-31",
      "last_synced_at": "2026-10-21T12:13:07.503Z",
      "location_count": 2,
      "location_summary": "Tampa, Florida • Atlanta, Georgia",
      "locations": [
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04798339"
    },
    {
      "nct_id": "NCT05961839",
      "title": "Study of SGR-2921 in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Acute Myeloid Leukemia",
        "High-Risk and Very High-Risk Myelodysplastic Syndromes"
      ],
      "interventions": [
        {
          "name": "SGR-2921",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Schrödinger, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 66,
      "start_date": "2023-09-27",
      "completion_date": "2025-09-09",
      "has_results": false,
      "last_update_posted_date": "2025-09-22",
      "last_synced_at": "2026-10-21T12:13:07.503Z",
      "location_count": 12,
      "location_summary": "Denver, Colorado • Fairway, Kansas • Buffalo, New York + 9 more",
      "locations": [
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Fairway",
          "state": "Kansas"
        },
        {
          "city": "Buffalo",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05961839"
    },
    {
      "nct_id": "NCT00747539",
      "title": "Brain Deficits in HIV/HCV Coinfected People Before and After Anti-HCV Therapy",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "HIV",
        "Hepatitis C",
        "Infections"
      ],
      "interventions": [
        {
          "name": "Pegylated interferon alfa and ribavirin (PEG-IFN/RBV)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of California, Los Angeles",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 330,
      "start_date": "2008-07",
      "completion_date": "2015-06",
      "has_results": false,
      "last_update_posted_date": "2016-05-13",
      "last_synced_at": "2026-10-21T12:13:07.503Z",
      "location_count": 4,
      "location_summary": "Lancaster, California • Los Angeles, California",
      "locations": [
        {
          "city": "Lancaster",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00747539"
    },
    {
      "nct_id": "NCT03431077",
      "title": "A Study of LJPC-501 in Pediatric Patients With Hypotension",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Catecholamine-resistant Hypotension (CRH)",
        "Distributive Shock",
        "High Output Shock",
        "Sepsis"
      ],
      "interventions": [
        {
          "name": "Angiotensin II",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "La Jolla Pharmaceutical Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "2 Years to 17 Years"
      },
      "enrollment_count": 2,
      "start_date": "2018-02-11",
      "completion_date": "2018-04-14",
      "has_results": false,
      "last_update_posted_date": "2018-08-07",
      "last_synced_at": "2026-10-21T12:13:07.503Z",
      "location_count": 3,
      "location_summary": "Charlotte, North Carolina • Cincinnati, Ohio • San Antonio, Texas",
      "locations": [
        {
          "city": "Charlotte",
          "state": "North Carolina"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03431077"
    },
    {
      "nct_id": "NCT02474901",
      "title": "Shedding, Immunogenicity and Safety of Quadrivalent Live Intranasal Influenza Vaccine (QLAIV) in HIV-infected Children and Young Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Human Immunodeficiency Virus (HIV)"
      ],
      "interventions": [
        {
          "name": "Quadrivalent Live Attenuated Influenza Vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "University of Colorado, Denver",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "25 Years",
        "sex": "ALL",
        "summary": "2 Years to 25 Years"
      },
      "enrollment_count": 101,
      "start_date": "2013-07",
      "completion_date": "2016-12",
      "has_results": true,
      "last_update_posted_date": "2017-11-20",
      "last_synced_at": "2026-10-21T12:13:07.503Z",
      "location_count": 1,
      "location_summary": "Denver, Colorado",
      "locations": [
        {
          "city": "Denver",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02474901"
    }
  ]
}